Journal
BLOOD
Volume 115, Issue 13, Pages 2569-2577Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-09-199182
Keywords
-
Categories
Funding
- British Heart Foundation [PG/04/129/18095, RG/07/002/23132]
- National Heart, Lung, and Blood Institute [HL58837, HL81326]
- British Heart Foundation [RG/07/002/23132] Funding Source: researchfish
Ask authors/readers for more resources
Factor XI (FXI) is the zymogen of an enzyme (FXIa) that contributes to hemostasis by activating factor IX. Although bleeding associated with FXI deficiency is relatively mild, there has been resurgence of interest in FXI because of studies indicating it makes contributions to thrombosis and other processes associated with dysregulated coagulation. FXI is an unusual dimeric protease, with structural features that distinguish it from vitamin K-dependent coagulation proteases. The recent availability of crystal structures for zymogen FXI and the FXIa catalytic domain have enhanced our understanding of structure-function relationships for this molecule. FXI contains 4 apple domains that form a disk structure with extensive interfaces at the base of the catalytic domain. The characterization of the apple disk structure, and its relationship to the catalytic domain, have provided new insight into the mechanism of FXI activation, the interaction of FXIa with the substrate factor IX, and the binding of FXI to platelets. Analyses of missense mutations associated with FXI deficiency have provided additional clues to localization of ligand-binding sites on the protein surface. Together, these data will facilitate efforts to understand the physiology and pathology of this unusual protease, and development of therapeutics to treat thrombotic disorders. (Blood. 2010; 115(13):2569-2577)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available